AsclepiX Therapeutics Overview
- Year Founded
-
2011
- Status
-
Out of Business
- Employees
-
8
- Latest Deal Type
-
Out of Business
- Investors
-
1
AsclepiX Therapeutics General Information
Description
Operator of a biopharmaceutical company intended to develop a novel and durable treatment for retinal diseases. The company uses computational biology to identify potent peptide regulators of vascular homeostasis, its integrin-regulating peptides designed to inhibit neovascularization by disrupting VEGF R2 (vascular endothelial growth factor receptor 2), reducing vascular permeability and leakage by promoting TIE2 (tunica intima endothelial kinase 2) clustering at intracellular junctions, and suppress vascular inflammation by inhibiting NFkB (nuclear factor kappa B)-mediated inflammation, enabling patients with preventive neovascularization and reduced vascular permeability.
Contact Information
Website
www.asclepix.comCorporate Office
- 5237 River Road
- Suite 334
- Bethesda, MD 20816
- United States
Corporate Office
- 5237 River Road
- Suite 334
- Bethesda, MD 20816
- United States
AsclepiX Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 12. Out of Business | 26-Apr-2026 | Completed | Out of Business | |||
| 11. Later Stage VC | Cancelled | Clinical Trials - Phase 1 | ||||
| 10. Later Stage VC (Series A3) | 26-Jul-2023 | Completed | Clinical Trials - Phase 1 | |||
| 9. Later Stage VC (Series A) | 24-Jun-2020 | Completed | Generating Revenue | |||
| 8. Later Stage VC (Series A) | 13-Nov-2018 | Completed | Generating Revenue | |||
| 7. Grant | 01-Jan-2018 | Completed | Generating Revenue | |||
| 6. Grant | 01-Jan-2017 | Completed | Generating Revenue | |||
| 5. Grant | 01-Sep-2015 | Completed | Generating Revenue | |||
| 4. Grant | 24-Jul-2014 | $1.01M | Completed | Generating Revenue | ||
| 3. Accelerator/Incubator | 25-Jun-2014 | Completed | Generating Revenue |
AsclepiX Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A3 | ||||||||
| Series A2 | ||||||||
| Series A-1 | 17,752,980 | $0.000100 | $1.97 | $1.97 | 1x | $1.97 | 26.61% |
AsclepiX Therapeutics Comparisons
Industry
Financing
Details
AsclepiX Therapeutics Competitors (63)
One of AsclepiX Therapeutics’s 63 competitors is Mighty Therapeutics, a Private Equity-Backed company based in Needham, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Mighty Therapeutics | Private Equity-Backed | Needham, MA | ||||
| Allegro Ophthalmics | Venture Capital-Backed | San Juan Capistrano, CA | ||||
| Unity Biotechnology | Formerly VC-backed | South San Francisco, CA | ||||
| Belite Bio | Formerly VC-backed | San Diego, CA | ||||
| Adverum Biotechnologies | Formerly VC-backed | Redwood City, CA |
AsclepiX Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
AsclepiX Therapeutics Patents
AsclepiX Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240226241-A1 | Formulations for intraocular delivery of peptides derived from type iv collagen | Inactive | 26-Aug-2022 | ||
| US-20260325600-A1 | Formulations for intraocular delivery of peptides derived from type iv collagen | Pending | 26-Aug-2022 | ||
| WO-2024044745-A2 | Formulations for intraocular delivery of peptides derived from type iv collagen | Inactive | 26-Aug-2022 | ||
| WO-2024044745-A3 | Formulations for intraocular delivery of peptides derived from type iv collagen | Inactive | 26-Aug-2022 | ||
| AU-2020248438-A1 | Compositions and methods for treating ocular disease | Inactive | 26-Mar-2019 | A61K38/39 |
AsclepiX Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
AsclepiX Therapeutics Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Johns Hopkins University | University |
AsclepiX Therapeutics FAQs
-
When was AsclepiX Therapeutics founded?
AsclepiX Therapeutics was founded in 2011.
-
Where is AsclepiX Therapeutics headquartered?
AsclepiX Therapeutics is headquartered in Bethesda, MD.
-
What is the size of AsclepiX Therapeutics?
AsclepiX Therapeutics has 8 total employees.
-
What industry is AsclepiX Therapeutics in?
AsclepiX Therapeutics’s primary industry is Drug Discovery.
-
Is AsclepiX Therapeutics a private or public company?
AsclepiX Therapeutics is a Private company.
-
What is AsclepiX Therapeutics’s current revenue?
The current revenue for AsclepiX Therapeutics is .
-
How much funding has AsclepiX Therapeutics raised over time?
AsclepiX Therapeutics has raised $50M.
-
Who are AsclepiX Therapeutics’s investors?
Johns Hopkins University has invested in AsclepiX Therapeutics.
-
Who are AsclepiX Therapeutics’s competitors?
Mighty Therapeutics, Allegro Ophthalmics, Unity Biotechnology, Belite Bio, and Adverum Biotechnologies are some of the 63 competitors of AsclepiX Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
